CTLA4 and neoplasm: However, since metformin activates anti-tumor immunity by different mechanisms from anti-PD-1/PD-L1 or anti-CTLA-4 mAbs, the combination of immune check point inhibitors and metformin may provoke remarkable radiosensitizing effects leading to improved outcomes in patients with LARC.